FDA 483 - Halo Pharmaceutical Canada Inc - September 28, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Halo Pharmaceutical Canada Inc, a contract drug manufacturer in Mirabel, Quebec, revealed significant deficiencies in quality control and manufacturing processes. Observations included failures to thoroughly investigate out-of-specification results for drug product impurities, incomplete cleaning validations for manufacturing equipment, and inadequately qualified production equipment. These issues indicate a lack of robust control over critical aspects of drug product manufacturing.
ID · da2c8c47-a0ad-42fb-9779-22cebc86c386